Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21;9(1):78.
doi: 10.1186/s41181-024-00308-5.

Numerical simulation method for the assessment of the effect of molar activity on the pharmacokinetics of radioligands in small animals

Affiliations

Numerical simulation method for the assessment of the effect of molar activity on the pharmacokinetics of radioligands in small animals

Tatsuya Kikuchi et al. EJNMMI Radiopharm Chem. .

Abstract

Background: It is well recognized that the molar activity of a radioligand is an important pharmacokinetic parameter, especially in positron emission tomography (PET) of small animals. Occupation of a significant number of binding sites by radioligand molecules results in low radioligand accumulation in a target region (mass effect). Nevertheless, small-animal PET studies have often been performed without consideration of the molar activity or molar dose of radioligands. A simulation study would therefore help to assess the importance of the mass effect in small-animal PET. Here, we introduce a new compartmental model-based numerical method, which runs on commonly used spreadsheet software, to simulate the effect of molar activity or molar dose on the pharmacokinetics of radioligands.

Results: Assuming a two-tissue compartmental model, time-concentration curves of a radioligand were generated using four simulation methods and the well-known Runge-Kutta numerical method. The values were compared with theoretical values obtained under an ultra-high molar activity condition (pseudo-first-order binding kinetics), a steady-state condition and an equilibrium condition (second-order binding kinetics). For all conditions, the simulation method using the simplest calculation yielded values closest to the theoretical values and comparable with those obtained using the Runge-Kutta method. To satisfy a maximum occupancy less than 5%, simulations showed that a molar activity greater than 150 GBq/μmol is required for a model radioligand when 20 MBq is administered to a 250 g rat and when the concentration of binding sites in target regions is greater than 1.25 nM.

Conclusions: The simulation method used in this study is based on a very simple calculation and runs on widely used spreadsheet software. Therefore, simulation of radioligand pharmacokinetics using this method can be performed on a personal computer and help to assess the importance of the mass effect in small-animal PET. This simulation method also enables the generation of a model time-activity curve for the evaluation of kinetic analysis methods.

Keywords: Mass effect; Molar activity; Numerical method; Simulation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Compartmental model for the simulation of radioligand kinetics. Cp, Cf and Cb are the concentrations of the radioligand in plasma, the free radioligand in an ROI and the bound radioligand in an ROI, respectively. Bavail is the concentration of available binding sites. K1, k2, k3 (= konBavail) and k4 (= koff) are rate constants
Fig. 2
Fig. 2
Time-activity curve (TAC) for Cp (A) and theoretical TACs for Ct in an ROI (B) used for Validation 1. Panels C and D show the relative errors of simulated values for Bmax = 5 nM and Bmax = 50 nM, respectively, when ∆t = 0.01 min throughout the observation period (5–60 min). Panels E and F show them when ∆t = 0.001 min for 0–5 min and ∆t = 0.01 min for 5–60 min. The relative errors simulated using Methods 1‒3 in the panels C and D almost completely overlap
Fig. 3
Fig. 3
TAC in plasma used for Validation 2 (A), simulated TACs in an ROI generated using Method 4 (B), TAC in plasma used for Validation 3 (C) and simulated TACs in an ROI generated using Method 4 (D)
Fig. 4
Fig. 4
TACs generated using Method 4 for Bmax = 5 nM (A) and Bmax = 50 nM (C) and time-courses of occupancies for Bmax = 5 nM (B) and Bmax = 50 nM (D), simulated using a molar activity (Am) in the 6.25–400 GBq/μmol range
Fig. 5
Fig. 5
Relationships between Am and the maximum occupancy (A) and between Am and Ct(60) (B) for Bmax values in the 1.25–160 nM range
Fig. 6
Fig. 6
The effect of kon, k4 and KD on the relationship between Am and maximum occupancy for Bmax = 5 nM (A) and Bmax = 50 nM (B). The same color represents the same KD value. The same symbol represents the same kon value. In panel B, the values for kon = 0.0125 and k4 = 0.0125 and for kon = 0.025 and k4 = 0.05 almost completely overlap, and the values for kon = 0.05 and k4 = 0.05 and for kon = 0.025 and k4 = 0.0125 almost completely overlap
Fig. 7
Fig. 7
Curve fitting of Ct(t) data simulated using Method 4 for Bmax = 5 nM (A) and Bmax = 50 nM (B). Symbols show simulated Ct(t) and Cb(t) values. Some simulated data points have been omitted to enable the fitted curves to be seen clearly. Lines for Ct(t) show the fitted curves, and lines for Cb(t) show the curves generated using the kinetic parameters estimated by fitting the Ct(t) curve

Similar articles

References

    1. Alexoff DL, Vaska P, Marsteller D, Gerasimov T, Li J, Logan J, Fowler JS, Taintor NB, Thanos PK, Volkow ND. Reproducibility of 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. J Nucl Med. 2003;44:815–22. - PubMed
    1. Alves IL, García DV, Parente A, Doorduin J, Dierckx R, Marques da Silva AM, Koole M, Willemsen A, Boellaard R. Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain. EJNMMI Res. 2017;7:17. - PMC - PubMed
    1. Ashworth S, Rabiner EA, Gunn RN, Plisson C, Wilson AA, Comley RA, Lai RYK, Gee AD, Laruelle M, Cunningham VJ. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med. 2010;51:1021–9. - PubMed
    1. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92. - PubMed
    1. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818–23. - PubMed

LinkOut - more resources